Yes you have a point there. This is mild to moderate and quite possibly not everyone who signed up for the trial got treated because they recovered too quickly. Don't know how that works.
Officially we should have 75 patients in the trial for a 2:1 LL vs Placebo, actual enrollment however was 86. But we don't know how many actually were treated, since we did not get the details.
Cytodyn has to confirm on this. I am inclined to think FDA is playing with the semantics in an unreasonable way, to avoid giving any semblance of success for Leronlimab.
News 
Market Data 
Discover 
AI
